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Abstract
Objectives: to estimate the cancer risk of HIV-infected
patients in the HaaRt era with respect to a general
reference population and to determine risk factors for
malignancy. 
Methods: long term (1996-2009) cancer incidence of
the bonn single centre HIV cohort was compared to
the incidence of the reference population of saarland
using standardized incidence ratios (sIR). Poisson re-
gression  analysis  was  used  to  identify  predictors  of
cancer risk. 
Results:  1,476  patients  entered  the  cohort,  enabling
8,772 person years of observation. 121 tumours in 114
patients, 7 in-situ and 114 invasive cancers, were iden-
tified. Malignancies associated with infectious agents
such  as  kaposi  sarcoma  (sIRs:  male:  5,683;  female:
277), non-Hodgkin lymphoma (sIRs male: 35; female:
18), anal cancer (sIRs male: 88; female: 115) as well a
cervical carcinoma (sIR female: 4) and Hodgkin’s dis-
ease  (sIR  male:  39)  and  liver  cancer  (sIR  male:  18)
were substantially more frequent in HIV-infected pa-
tients than in the general population (p< 0.001, each),
whereas all other types of cancer were not increased.
Poisson regression identified HaaRt (incidence rate
ratio IRR (95% CI): 0.28 (0.19-0.41), p<0.001), Cd4
count (IRR per 100 cells/µl increase: 0.66 (0.57-0.76),
p<0.001), hepatitis b (IRR: 2.15 (1.10-4.20), p= 0.046)
and age (IRR per 10 year increase: 1.23 (1.03 – 1.46), p
= 0.023) as independent predictors for the occurrence
of any type of cancer. 
Conclusions: HaaRt and preserved Cd4 cells prefer-
entially reduce the risk of malignancies associated with
oncogenic infections. 
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HaaRt 
IntRoduCtIon
Highly active antiretroviral therapy (HaaRt) has dra-
matically reduced the risk for opportunistic infections
and improved overall life expectancy in patients with
HIV-infection and aIds [1)]. However, the effects of
HaaRt on the known increased rate of malignancies
in HIV infected individuals are less clear, and due to
the improved life expectancy the burden of malignan-
cy may become more evident [2-4]. 
Certain types of cancer, which are rare in the gener-
al  population  such  as  kaposi  sarcoma  and  non-
Hodgkin lymphoma, are apparently linked to immun-
odeficiency in advanced HIV infection and have been
included in the definition of aIds [5]. In addition to
aIds defining cancers about 20 other types of malig-
nancy, particularly those associated with oncogenic in-
fectious agents, occur more frequently in HIV-infected
patients and are probably also linked to immunodefi-
ciency. several studies suggest cancer incidence rates
to decline under HaaRt but still to remain above the
levels of the normal population [6-8]. However, spe-
cific HIV-associated factors potentially contributing to
the risk of cancer such as current Cd4 t-cell counts
or  co-infections  with  oncogenic  viruses  have  only
been taken into account by few studies todate. such
information is urgently needed to better guide initia-
tion of antiretroviral treatment. to address this issue
we assessed the incidence of cancer in a large single-
center  HIV  cohort  during  the  HaaRt  era,  and  in-
cluded in our analysis all types of cancer i.e. those as-
sociated  with  oncogenic  infections  as  well  as  malig-
nancies due to other aetiologies. data were compared
to  the  largest  existing  german  cancer  registry  and
were  stratified  with  respect  to  sex,  actual  use  of
HaaRt, evolution of Cd4 counts and co-infections
to compensate for potential confounding effects.
PatIEnts and MEtHods
Patients in the bonn HIV cohort are followed on a
regular  basis.  after  informed  consent  has  been  ob-
tained, the state of HIV infection, antiretroviral thera-
py, and any clinical complication including cancer and
death are recorded in 3 month intervals for each pa-
tient and then entered prospectively in the local HIV
data base. 
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patients which had been entered in the bonn HIV data
base  between  January  1st,  1996  and  december  31st
2008 were evaluated. data were retrieved from elec-
tronic  database  entries  (retrolective)  by  means  of  a
structured questionnaire, which comprised general de-
mographic  data,  characteristics  of  HIV-infection,
presence and details of any tumor entity (anatomical
site, diagnosis date, stage and morphologic type). Ma-
lignant  tumors  were  classified  according  to  the
anatomical site of the cancer ICd (9th edition) and tu-
mor morphology (based on ICd-o 3rd edition) in the
case of kaposi sarcoma (table 1). Multiple primaries,
i.e. cancers of a different type occurring in an individ-
ual  with  a  previous  diagnosis  of  malignant  disease,
were included in the analysis. Cancer incidences were
calculated, excluding prevalent cases at the start of ob-
servation.  In  order  to  ensure  correct  capturing  of
newly developed cancer at the end of the observation
period, data were collected until March 31st 2009, i.e. 3
months after the end of the statistical evaluation peri-
od. Patient data were analyzed in a dynamic fashion,
i.e. the same person could contribute to different cate-
gories  of  risk  factors  depending  on  his/her  actual
classification of Cd4-cell counts and other time-de-
pendent variables at each single time point throughout
the entire observation period. the population based
saarland Cancer Registry which registers invasive and
in-situ malignant neoplasms since 1967 provided can-
cer incidence of a reference population. Completeness
of case ascertainment of the saarland Cancer Registry
has been estimated to be above 95 % [9, 10]. In order
to compare the tumour incidence of the bonn cohort
with the reference population, we calculated sex and
age adjusted standardized incidence ratios (sIR) and
corresponding  95%  confidence  intervals  by  tumour
site  and  sex  [11].  observation  times  were  classified
and aggregated according to the World Health organi-
zation conventions [11].  
PoIsson REgREssIon ModEl
an aggregated Poisson model was used to estimate in-
cidence rate ratios (IRR) of different Cd4 categories
(0 – 50cells/µl, 51 – 100cells/µl, 101 – 200cells/µl,
201 – 350cells/µl, 351 – 700cells/µl and >700cells/
µl) in comparison to the reference population, adjust-
ed for HIV-infection status and age. 
In a second model we restricted the analysis to the
HIV-positive bonn cohort in order to account for ad-
ditional potential confounders and to validate findings
of the first model with a non-aggregated analysis. the
association between Cd4 counts and cancer incidence
was considered as target association, adjusted for the
eligible putative confounders (sex, age, HCV co-infec-
tion, HbV co-infection, HaaRt, history of aIds or
Cd4 counts < 200 cells/µl). Patients were considered
to take HaaRt within a given year if the use of three
antiretroviral  drugs  from  two  different  drug  classes
(nucleoside  reverse  transcriptase  inhibitors,  non-nu-
cleoside  reverse  transcriptase  inhibitors  protease  in-
hibitors,  fusion  or  entry  inhibitors  or  integrase  in-
hibitors) or more than two nucleoside reverse tran-
scriptase inhibitors had been documented for at least
two  consecutive  3-month  observation  periods. 
Chronic  hepatitis  b  virus  (HbV)  infection  was  de-
fined by the presence of Hepatitis b surface antigen,
the diagnosis of chronic hepatitis C (HCV) virus in-
fection required detection of HCV antibody in com-
bination  with  HCV-Rna.  to  identify  relevant  con-
founders  for  the  target  association  of  Cd4  cell-
count  and  cancer  risk  exact  estimates  of  incidence
rates (IR) and incidence rate ratios (IRR) were calcu-
lated  adjusted  for  ties  and  dynamic  subject  effects.
Mantel-Haenszel adjustment was used to account for
strata effects variable by variable. the model was a
Poisson  process  with  random  effects  using  general-
ized  estimating  equations.  Robustness  of  parameter
estimates concerning malignancy of any type and of
the Poisson modeling process were checked by accel-
erated-bias-controlled  bootstrapping  (5,000  replica-
tions).  statistical  analysis  was  performed  using  the
stata  11.0  software  package  (stataCorp  lP,  texas,
usa) and the R programming language and software
environment  for  statistical  computing  (release
2.8.0)[12].
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Table 1. ICd9 codes used for cancer definition.
Cancer category ICD-9 codes
kaposi sarcoma M9140#
non-Hodgkin lymphoma 200 / 202
anal cancer 154.2 - 154.8; 
230.5  - 6
Hodgkin lymphoma 201
liver cancer 155
Cancer of the Cervix 180, 233.1
lung cancer 162.2 – 162.9
oropharyngeal cancer 140 - 149; 161; 231.0
Colorectal cancer 153 / 154.0 – 154.1; 231.0
thyroid cancer 193
Cancer unknown primary 199.0 – 199.1
breast 174; 233.0
Endometrium 182; 232.2
Melanoma 172.0; 232 (M8720#-M8790#)
Renal 189; 233.9
Infection-related cancer
kaposi sarcoma. non- M9140# / 154.2 – 
Hodgkin lymphoma.  154.8 / 155.0 / 180 / 
Hodgkin lymphoma. anal  200 - 201 / 202.0 / 
cancer. cancer of the cervix.  202.8 / 230.5/6 / 
liver cancer 233.1
Non-Infect. related cancer
lung cancer. oropharyngeal  140 – 153 / 154.0 – 
cancer. colorectal cancer.  154.1 / 155.1 – 
thyroid cancer. breast  155.2 / 156 – 179 / 
cancer. endometrium  181 - 199 / 202.1 - 
cancer. melanoma. renal  202.6 / 202.9 / 203 – 
cancer and other non- 208 / 230.0 – 230.5 / 
infectious related cancers 230.6 – 230.9 / 231 / 
232 / 233.2 – 233.9 / 234
all cancer 140 – 208 / 230 - 
234
#  Morphology  code  used  alternatively  as  a  specific  ICd9
code in the 1979 edition for kaposi sarcoma was not avail-
able
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during the 13 year observation period 1,476 patients
(81% male, 19% female) presented to our clinic. a me-
dian of 11 (range 1 – 86) medical examinations were
recorded per patient resulting in a total of 24,572 ex-
aminations. the total observation time was 8,772 per-
son years of follow-up. demographic characteristics
are summarized in table 2.
during the observation period 121 tumors (114 in-
vasive, 7 in-situ) were observed in 114 patients. seven
patients suffered from a second malignancy. the annu-
al  rate  of  cancer  incidence  (1908/100,000  person
years)  did  not  change  over  the  observation  period.
Comparing the cancer incidence rates in the bonn co-
hort  with  the  general  population  of  saarland,  more
malignancies  were  observed  among  HIV-positive  pa-
tients of the bonn cohort (table 3). However, conspic-
uous  differences  in  the  standardized  incidence  ratio
(sIR) were revealed, when the observed tumors were
classified into infection-related types and cancer unre-
lated to infectious diseases: Whereas cancers occurring
as  a  complication  of  human  herpes  virus  8  (kaposi
sarcoma), Epstein barr virus (non-Hodgkin lymphoma
and Hodgkin´s disease), hepatitis b and C viruses (he-
patocellular  carcinoma)  and  human  papilloma  virus
(anal carcinoma and carcinoma of the cervix) were ob-
served significantly more frequently among HIV-posi-
tive patients (p<0.001 each), cancers unrelated to in-
fectious disesase occurred at similar rates as in the ref-
erence  population..  the  incidence  of  cancer  entities
unrelated to infectious diseases was apparently not cor-
related to the degree of immunodeficiency (fig. 1c). In
contrast, incidence rate ratios of infection-related can-
cers were closely correlated to the degree of immunod-
eficiency  as  reflected  by  Cd4  counts  (p<0.001  for
trend, fig. 1b). the cancer risk increased the more the
lower  Cd4-cell  counts  had  dropped  below  350  /µl
(fig.  1a).  of  note,  however,  the  risk  for  cancer  re-
mained above the level of the reference population for
all Cd4 strata. to take into account the potential con-
tribution  from  confounding  parameters  we  first  per-
formed  univariate  comparisons  to  identify  putative
confounding variables to be further explored in a mul-
tivariate  regression  model.  We  investigated  whether
sex,  age  or  HCV  co-infection  were  associated  with
Cd4 cell-count as the putative cause and the occur-
rence of cancer as the effect and found that none of
these potential confounders, interfered with both the
putative cause “Cd4 cell-count” and the effect “can-
cer”. In contrast, “history of aIds” or “history of a
Cd4 cell-count below 200 /µl”, “HbV co-infection”
and “use of HaaRt” were strongly associated with
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Table  2.  baseline characteristics of the bonn cohort at the
start of observation.
Bonn cohort
n = 1476
age [yrs] 36 (16 – 85)
Male sex [%] 81
Race [%]
Caucasian 85
afro-american 11
asian 2
Hispanic 1
other / unknown 1
transmission-Risk [%]
homosexual 47
heterosexual 14
endemic 12
blood products 11
i.v. drug abuse 10
unknown 5
Hepatitis Coinfection [%]
HbV 4
HCV 21
aIds or Cd4 < 200/µl [%] 35
HaaRt [%] 40
3 x / 4x nRtI 6
nnRtI 25
PI 65
salvage 3
Cd4-cells [/µl] 359
HIV-Rna [log10] 3.9
Continuous variables are given as median (range). categorical
variables as percent of patients (95% confidence interval). 
abbreviations:  i.v.  intravenous;  HbV  hepatitis  b  infection;
HCV hepatitis C infection; aIds acquired immunodeficiency
syndrome; HaaRt highly active antiretroviral therapy. 
Fig.  1a-c. Incidence rate ratios male patients, stratified ac-
cording to HIV- and Cd4-status: a) all cancer, b) infection
related, c) cancer unrelated to infectious diseases.
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because aIds and Cd4 cell-count below 200/µl re-
flect the natural course of HIV infection this parame-
ter was not considered within the multivariate model.
HaaRt on the other hand is known to counteract the
natural course of HIV-infection and was thus included
in  the  model.  after  adjustment  for  potential  con-
founders  a  significant  influence  of  the  current  Cd4
cell-count  on  the  risk  for  cancer  remained.  Per  100
Cd4-cell increase the incidence rate decreased by 34%
(IRR 0.66, 95% CI 0.56 – 0.78, p < 0.001) and 46%
(IRR 0.54, 95% CI 0.46-0.65) for all types of cancer
and infection-related cancers, respectively. Inclusion of
“history of aIds” or “Cd4 cell-count below 200/µl”
did not change the significant impact of current Cd4
cell-count on the risk for cancer or infection-related
cancer (IRR 0.74, 95% CI 0.64 – 0.85 and IRR 0.62,
95% CI 0.52 – 0.74 respectively). HbV co-infection,
age and use of HaaRt independently increased and
decreased the cancer risk, respectively (table 5). the
protective effect of HaaRt was most pronounced in
infection-related  types  of  cancer,  where  HaaRt  re-
duced the risk for cancer by 76%. In contrast, while
the risk for cancer unrelated to infectious diseases ap-
pear to be not affected by current Cd4 cell-counts, use
of HaaRt may also slightly attenuate the cancer risk
for these cancer entities (decrease by 48% (IRR 0.42,
95% CI 0.17 – 1.06, p = 0.065). 
dIsCussIon
In the bonn HIV cohort individuals had a significantly
higher risk for cancer as compared to the normal pop-
ulation with an overall standardized incidence ratio of
4 for women and 6 for men. the cancer risk varied
considerable depending on the type of cancer. Cancers
with  an  underlying  infectious  pathogen  occurred
roughly 30 (female) - 100 (male) times more frequently
among HIV-positive individuals compared to the nor-
mal population (table 3). on the contrary, cancer types
unrelated to infectious diseases were found at a similar
rate as in the normal population. the observed inci-
dence rates of cancer in the bonn HIV cohort were
well within the range of data reported recently from
large us-american and french aIds and tumor reg-
istries [7, 13]. However, the observed rate for kaposi
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Table 3. Cancer incidence. standardized incidence ratios (sIR) and corresponding 95% confidence intervals by primary site and
sex 
Sex Malignancy Observed Events Expected SIR (95% CI) p-Value
Bonn cohort Events*
1996 - 2008
n  n
Male kaposi 41 <0.1 5682.6 (4076.3 – 7555.2) < 0.001
nHl 28 0.8 35.0 (23.3 – 49.2) < 0.001
Hodgkin 8 0.2 38.7 (16.5 – 70.2) < 0.001
liver 7 0.4 18.2 (7.2 – 34.1) < 0.001
anal 6 0.1 87.8 (31.6 – 172.1) < 0.001
lung 5 3.3 1.5 (0.5 – 3.1) 0.509
oropharyngeal 3 2.4 1.1 (0.2 – 2.7) 0.905
Colorectal 3 2.7 1.1 (0.2 – 2.8) 0.920
CuP 2 0.6 3.5 (0.3 – 10.1) 0.215
Melanoma 1 2.1 0.5 (0.0 – 1.9) 0.682
thyroid 1 0.2 5.2 (0.0 – 20.6) 0.478
Renal 1 0.9 1.1 (0.0 – 4.3) 0.660
all cancer 106 24.1 4.4 (3.6 – 5.3) < 0.001
Infection-related 89 1.2 75.5 (60.6 – 92.0) < 0.001
non-Infect. related 17 21.6 0.8 (0.5 – 1.2) 0.374
female Cervix 6 1.5 4.0 (1.5 – 7.9) 0.001
kaposi 2 < 0.1 277.2 (26.1 – 794.5) < 0.001
nHl 2 0.1 18.2 (1.7 – 52.1) < 0.001
anal 2 < 0.1 115.2 (10.9 – 330.1) < 0.001
breast 1 1.5 0.7 (0.0 – 2.6) 1.000
Endometrium 1 0.2 5.3 (0.0 – 20.9) 0.472
thyroid 1 0.1 8.0 (0.0 – 31.4) 0.289
all cancer 15 6.0 2.5 (1.4 – 3.9) < 0.001
Infection-related 12 1.6 7.3 (3.8 – 12.0) < 0.001
non-Infect. related 3 4.1 0.7 (0.1 – 1.8) 0.780
* Expected events within the bonn cohort based on the age-specific rates of the saarland population (11).
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457 – 845 per 100.000 person-years) than that reported
by guiguet et al. (232, 95% CI 213 – 251) but lower
than that reported by Patel et al. (1252, 95% CI 1196 –
1309). likewise, the incidence rates of non-Hodgkin
lymphoma (454, 95% CI 292 – 617 vs. 209, 95% CI
192 – 228) and carcinoma of the cervix (475, 95% CI
177 – 1030 vs. 93 95% CI 71 - 115) were higher in our
cohort  than  in  the  french  cohort  [13].the  different
rates of kaposi sarcoma most likely reflect differences
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Table 4. Confounder identification.
CD4-cells CD4-cells Univariate
0-50 50+
n = 164 n = 1.312 p-value
Male sex [%] 79  81  0.602
age [years] 36 (19 – 77) 36 (16 – 85) 0.316
HCV [%] 16  21  0.124
aIds or Cd4 < 200/µl [%] 91  33  < 0.001
HbV [%] 7  4  0.056
HaaRt [%] 62 42 < 0.001
3 x / 4x nRtI 57 0.327
nnRtI 19 26
PI 75 64
salvage 14
Cancer No cancer Univariate
n = 114 n = 1.362 p-value
Male sex [%] 88  80  0.048
age [years] 39 (19 – 69) 36 (16 – 85) 0.004
HCV [%] 18 21  0.404
aIds or Cd4 < 200/µl [%] 62  33  < 0.001
HbV [%] 9  4  0.011
HaaRt [%] 32 45 0.006
3 x / 4x nRtI 07 0.255
nnRtI 18 25
PI 65 65
salvage 6  3
data shown as median (range) or percent where applicable. all comparisons refer to the time of first observation. fisher´s exact
test or two-sample t-test were used for statistical comparison.
Table 5. Effect of current Cd4 cell-count on the incidence of cancer. adjusted for presumed eligible confounders.
Parameter IRR 95% CI p-value
all cancer Cd4 [per 100 cells/µl] 0.66 0.57 – 0.76 < 0.001
HbV co-infection 2.15 1.10 – 4.20 0.024
use of HaaRt 0.28 0.19 – 0.41 < 0.001
age [per 10 years] 1.23 1.03 – 1.46 0.023
Infectious related cancer Cd4 [per 100 cells/µl] 0.54 0.46 – 0.65 < 0.001
HbV co-infection 1.99 1.02 – 3.90 0.045
use of HaaRt 0.24 0.16 – 0.37 < 0.001
age [per 10 years] 1.10  0.91 – 1.34 0.334
non-infectious related cancer Cd4 [per 100 cells/µl] 1.11 0.97 – 1.26 0.125
HbV co-infection 3.08 0.73 – 13.1 0.129
use of HaaRt 0.42 0.17 – 1.06 0.065
age [per 10 years] 1.99 1.52 – 2.61 < 0.001
IRR incidence rate ratio; CI confidence interval
2) Spengler_Umbruchvorlage  14.03.11  11:55  Seite 105in  the  study  populations  and  in  observation  period.
Whereas 32% of patients in the french cohort were
men who had sex with men (MsM), in our cohort 47%
of patients were MsM, which carry an increased risk to
develop  kaposi  sarcoma  as  compared  to  female  pa-
tients  and  other  HIV-positive  patients  with  different
transmission risks [13-15]. Moreover, our observation
time was confined to the HaaRt era, while Patel. and
colleagues had investigated a larger time-span encom-
passing both the pre-HaaRt and HaaRt era. When
comparing the incidence rates confined to the HaaRt
era, the rates of kaposi sarcoma were comparable be-
tween  both  studies,  since  incidence  rates  of  kaposi
sarcoma decreased after the introduction of HaaRt
[7].  likewise,  different  rates  of  non-Hodgkin  lym-
phoma, seem to reflect differences in the gender pro-
portions and risk factors of transmission [13]. on the
other hand the difference in the rates for cancer of the
cervix has to be attributed to the fact that unlike the
french cohort we had also included carcinoma in-situ,
since incidence rates for invasive cancer of the cervix
were rather similar between the french and bonn co-
hort (sIR 1.58, 95% CI 0.18 – 5.68, table 3). 
the risk for cancer was particular pronounced for
tumor entities related to infectious diseases which are
probably  particularly  affected  by  immunodeficiency
[16]. though the risk for cancer in this category was
increased regardless of Cd4 cell-count, the cancer risk
further  increased  gradually  when  Cd4-cell  counts
dropped  below  normal  and  was  highest  among  pa-
tients with Cd4-cell counts below 50 cells/µl. Howev-
er, the sample size and length of observation period
were  not  sufficient  to  distinguish  differences  in  the
Cd4 threshold for the increase in risk of distinct can-
cer types. 
unlike our study guiguet et al. also reported a sig-
nificant impact of Cd4-cell counts on the risk of lung
cancer  [13],  which  was  approximately  ten-fold  in-
creased in patients with Cd4 cell-counts < 50 /µl. al-
though  the  crude  incidence  of  lung  cancer  had  the
same order of magnitude in both studies (57.0 vs 81.1
per 100,000 person years), the number of our patients
may have been too small as to reveal this effect. simi-
larly, in contrast to previous studies [17] our study did
not find an increased risk for thyroid cancer, endome-
trial cancer and CuP, which may be attributable to the
small numbers of these tumor types in our cohort.  
HaaRt  attenuated  the  cancer  risk  independently
from Cd4 cell-counts in line with previous observa-
tions [13, 18, 19]. nevertheless, the threshold when to
start HaaRt to reduce the risk of malignancy is less
clear. Current guidelines of the European aIds Clini-
cal society recommend HaaRt in the absence of ad-
ditional  risk  factors  if  Cd4-cell  counts  drop  below
350 cells/µl, [20]. In contrast, us-american guidelines
recommend  HaaRt  at  a  thresholf  of    500  Cd4
cells/µl,  although  the  panel  was  divided  whether  to
make this a strong or moderate recommendation [21].
Considering tumor risk as a factor for HaaRt indica-
tion, our data suggest only little increase for Cd4 cell-
counts above 350 /µl and thus would rather favour the
European  recommendations.  However,  it  has  to  be
taken  into  account  that  for  some  tumors  important
pathogenetic steps may occur at early stages, if not
immediately after HIV-infection, when large amounts
of the immune-repertoire are lost rapidly within the
first few days of HIV infection [22]. of note, we re-
ported an increased risk for all types of cancer and in-
fection-related  cancer  in  patients  with  chronic  HbV
infection. We assume that HbV- infection in patients
with non-infectious types of cancer might have been a
surrogate marker for a certain life style. among the 16
cancer patients with chronic hepatitis b, five patients
developed  kaposi  sarcoma;  2  developed  nHl,  2
HCC, 3 anal carcinoma, and 3 patients suffered from
oropharyngeal cancer. thus, also in the case of infec-
tion-associated types of cancers, HCC only was the ul-
timate tumor only in few patients. otherwise, 8 of the
patients  with  hepatitis  b  had  homosexual  contacts,
which is a risk factor for ks and anal carcinoma sug-
gesting a life style related causality.
ConClusIons
the risk of cancer in the setting of HIV-infection is
reduced  by  antiretroviral  therapy  but  remains  above
that  of  the  HIV-uninfected  reference  population  in
the case of tumor entities with an underlying infec-
tious etiology irrespective if these tumors have been
classified as aIds-defining or not. In the subgroup
with infection-related malignancies the tumor risk is
clearly correlated to the degree of immunodeficiency
at  the  time  of  tumor  appearance,  whereas  tumors
without an underlying infectious cause occurred at a
similar frequency as in the reference population and
did not show a clear relationship to Cd4 counts. fur-
ther large studies are justified to define the optimum
Cd4 threshold for start of HaaRt in order to reduce
the risk for distinct infection-related malignancies.
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